CRL · NYSE · STOCK
Charles River Laboratories (CRL) Stock Analysis
$302.13
52W $146.20 – $333.30
56/100
$14.54B
-62.4
1.40
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is CRL Bullish or Bearish?
Bullish.
Innellis AI committee rates Charles River Laboratories (CRL) Buy with a composite score of 56/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +19.49 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -0.51 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is price structure making higher highs and higher lows. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- ROE of only -7.7% -- cheap may mean cheap for a reason — Value
- Revenue declining -0.7% YoY -- this is not a growth story right now — Growth
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
56/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 62%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -7.7% -- cheap may mean cheap for a reason
Growth Analyst
bullish
60
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
− Revenue declining -0.7% YoY -- this is not a growth story right now
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Weekly RSI at 77 -- overbought on the larger timeframe too
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 15.8% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 55.5 to 55.5.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
59.2
Neutral
MACD Histogram
0.694
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$259.98
Resistance
$302.63
Bollinger %B
0.78
Inside Bands
Price vs Moving Averages
EMA 9
$298.13
Above
EMA 21
$292.26
Above
EMA 50
$277.52
Above
EMA 200
$225.60
Above
Fundamental Analysis
Valuation
81
Growth
82
Profitability
8
Financial Health
59
Cash Flow
70
Valuation
P/E Ratio
-62.4×
P/B Ratio
5.15×
PEG Ratio
0.65
Dividend Yield
0.00%
52W High
$333.30
52W Low
$146.20
Quality & Growth
ROE
-456.1%
ROA
-202.3%
Gross Margin
3224.2%
Operating Margin
1234.8%
Revenue Growth YoY
—
Debt / Equity
1.07
AI Fundamental Assessment
P/E ratio of -62.4 (inexpensive relative to a 15-40x range); Price-to-book of 5.2x; PEG ratio of 0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -4.6%; Return on assets of -2.0%; Net margin of -6.0%; Gross margin of 32.2%; Current ratio of 1.35 (tight short-term liquidity); Debt-to-equity of 1.07; Free cash flow per share is positive (7.64); Most recent quarter beat estimates by 9.2%; 5 consecutive earnings beats; EPS growth accelerating (-13.8% -> +46.6% QoQ); Average YoY EPS growth of -3.2%; Analyst estimates rising over recent quarters
Get the Full CRL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →